Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer : Reports from Pfizer Describe Recent Advances in Hormones (Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2017 | 11:52pm CEST

Reports from Pfizer Describe Recent Advances in Hormones (Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Hormones have been published. According to news originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, "To examine the role that enzyme Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT1) plays in postprandial gut peptide secretion and signaling. The standard experimental paradigm utilized to evaluate the incretin response was a lipid challenge."

Our news journalists obtained a quote from the research from Pfizer, "Following a lipid challenge, plasma was collected cardiac puncture at each time point from a cohort of 5-8 mice per group from baseline at time zero to 10 h. Incretin hormones [glucagon like peptide-1 (GLP-1), peptide tyrosine-tyrosine (PYY) and glucose dependent insulinotropic polypeptide (GIP)] were then quantitated. The impact of pharmacological inhibition of DGAT1 on the incretin effect was evaluated in WT mice. Additionally, a comparison of loss of DGAT1 function either by genetic ablation or pharmacological inhibition. To further elucidate the pathways and mechanisms involved in the incretin response to DGAT1 inhibition, other interventions [inhibitors of dipeptidyl peptidase-IV (sitagliptin), pancreatic lipase (Orlistat), GPR119 knockout mice] were evaluated. DGAT1 deficient mice and wildtype C57/BL6J mice were lipid challenged and levels of both active and total GLP-1 in the plasma were increased. This response was further augmented with DGAT1 inhibitor PF-04620110 treated wildtype mice. Furthermore, PF-04620110 was able to dose responsively increase GLP-1 and PYY, but blunt GIP at all doses of PF-04620110 during lipid challenge. Combination treatment of PF-04620110 and Sitagliptin in wildtype mice during a lipid challenge synergistically enhanced postprandial levels of active GLP-1. In contrast, in a combination study with Orlistat, the ability of PF-04620110 to elicit an enhanced incretin response was abrogated. To further explore this observation, GPR119 knockout mice were evaluated. In response to a lipid challenge, GPR119 knockout mice exhibited no increase in active or total GLP-1 and PYY. However, PF-04620110 was able to increase total GLP-1 and PYY in GPR119 knockout mice as compared to vehicle treated wildtype mice."

According to the news editors, the research concluded: "Collectively, these data provide some insight into the mechanism by which inhibition of DGAT1 enhances intestinal hormone release."

For more information on this research see: Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion. World Journal of Gastrointestinal Pathophysiology, 2017;8(4):161-175 (see also Drugs and Therapies - Hormones).

The news correspondents report that additional information may be obtained from B.S. Maciejewski, Pfizer Worldwide Research and Development, Cardiovascular and Metabolic Diseases Research Unit, Cambridge, MA 02139, United States. Additional authors for this research include T.B. Manion and C.M Steppan.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.4291/wjgp.v8.i4.161. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Hormones, Peptides, Proteins, Cambridge, Incretins, Proteomics, Pharmacology, Massachusetts, United States, Acyltransferases, Drugs and Therapies, Enzymes and Coenzymes, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
02:05pPFIZER : U.S. FDA Approves Pfizer's Biosimilar NIVESTYM (filgrastim-aafi)
AQ
10:27aMERCK : Vyriads colorectal cancer oncolytic virus Voyager-V1
AQ
10:27aSPARK THERAPEUTICS : Pfizer initiates Phase III programme for Sparks haemophilia..
AQ
10:26aPFIZER : and Eli Lilly report positive results from Phase III tanezumab
AQ
09:45aPFIZER : Lambeth, Hanes forfeit money Reps. Lambeth and Hanes forfeit illegal ca..
AQ
08:07aPFIZER : Trump plan fails to lower prescription drug prices
AQ
07/20PFIZER : U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim..
BU
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
07/20PFIZER : An Application for the Trademark "RUXIENCE" Has Been Filed by Pfizer
AQ
More news
News from SeekingAlpha
08:59aSTOCKS TO WATCH : FANGs Out In Tech 
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/20FDA OK's Pfizer's Neupogen biosimilar 
07/20YOUR DAILY PHARMA SCOOP : Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Posit.. 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
Financials ($)
Sales 2018 54 297 M
EBIT 2018 20 769 M
Net income 2018 12 887 M
Debt 2018 21 973 M
Yield 2018 3,66%
P/E ratio 2018 17,18
P/E ratio 2019 15,61
EV / Sales 2018 4,43x
EV / Sales 2019 4,22x
Capitalization 219 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER3.06%218 540
JOHNSON & JOHNSON-9.93%337 790
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171
AMGEN9.54%126 889